Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-01-02
2007-01-02
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S045000, C514S046000, C514S048000
Reexamination Certificate
active
10602136
ABSTRACT:
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
REFERENCES:
patent: 3480613 (1969-11-01), Walton et al.
patent: 5977061 (1999-11-01), Holy et al.
patent: 6340690 (2002-01-01), Bachand et al.
patent: 6348587 (2002-02-01), Schinazi et al.
patent: 6395716 (2002-05-01), Gosselin et al.
patent: 6444652 (2002-09-01), Gosselin et al.
patent: 6495677 (2002-12-01), Ramasamy et al.
patent: 6573248 (2003-06-01), Ramasamy et al.
patent: 6660721 (2003-12-01), Devos et al.
patent: 6777395 (2004-08-01), Bhat et al.
patent: 6784166 (2004-08-01), Devos et al.
patent: 6846810 (2005-01-01), Martin et al.
patent: 6911424 (2005-06-01), Schinazi et al.
patent: 2002/0019363 (2002-02-01), Ismaili et al.
patent: 2002/0055483 (2002-05-01), Watanabe et al.
patent: 2002/0095033 (2002-07-01), Ramasamy et al.
patent: 2002/0147160 (2002-10-01), Bhat et al.
patent: 2002/0198171 (2002-12-01), Schinazi et al.
patent: 2003/0008841 (2003-01-01), Devos et al.
patent: 2003/0028013 (2003-02-01), Wang et al.
patent: 2003/0050229 (2003-03-01), Sommadossi et al.
patent: 2003/0060400 (2003-03-01), LaColla et al.
patent: 2003/0083307 (2003-05-01), Devos et al.
patent: 2003/0087873 (2003-05-01), Stuyver et al.
patent: 2003/0225029 (2003-12-01), Stuyver et al.
patent: 2003/0236216 (2003-12-01), Devos et al.
patent: 2004/0002476 (2004-01-01), Stuyver et al.
patent: 2004/0023921 (2004-02-01), Yao et al.
patent: 2004/0059104 (2004-03-01), Cook et al.
patent: 2004/0063658 (2004-04-01), Roberts et al.
patent: 2004/0067901 (2004-04-01), Bhat et al.
patent: 2004/0072788 (2004-04-01), Bhat et al.
patent: 2004/0110717 (2004-06-01), Bhat et al.
patent: 2004/0110718 (2004-06-01), Devos et al.
patent: 2004/0121980 (2004-06-01), Martin et al.
patent: 2004/0147464 (2004-07-01), Roberts et al.
patent: 2004/0266722 (2004-12-01), Devos et al.
patent: 2005/0119200 (2005-06-01), Roberts et al.
patent: 1521076 (1968-04-01), None
patent: 1581628 (1969-09-01), None
patent: 2662165 (1991-11-01), None
patent: 1163103 (1969-09-01), None
patent: 1209654 (1970-10-01), None
patent: 63-215694 (1988-09-01), None
patent: 06-228186 (1994-08-01), None
patent: WO 98/16184 (1998-04-01), None
patent: WO 99/43691 (1999-02-01), None
patent: WO 00/09531 (2000-02-01), None
patent: WO 01/32153 (2001-05-01), None
patent: WO 01/91737 (2001-06-01), None
patent: WO 01/92282 (2001-06-01), None
patent: WO 01/60315 (2001-08-01), None
patent: WO 01/68663 (2001-09-01), None
patent: WO 01/79246 (2001-10-01), None
patent: WO 01/90121 (2001-11-01), None
patent: WO 01/96353 (2001-12-01), None
patent: WO 02/03997 (2002-01-01), None
patent: WO 02/18404 (2002-03-01), None
patent: WO 02/32920 (2002-04-01), None
patent: WO 02/48165 (2002-06-01), None
patent: WO 02/057287 (2002-07-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/070533 (2002-09-01), None
patent: WO 02/094289 (2002-11-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 03/026589 (2003-04-01), None
patent: WO 03/026675 (2003-04-01), None
patent: WO 03/051899 (2003-06-01), None
patent: WO 03/061385 (2003-07-01), None
patent: WO 03/061576 (2003-07-01), None
patent: WO 03/062255 (2003-07-01), None
patent: WO 03/062256 (2003-07-01), None
patent: WO 03/062257 (2003-07-01), None
patent: WO 03/063771 (2003-08-01), None
patent: WO 03/068162 (2003-08-01), None
patent: WO 03/068164 (2003-08-01), None
patent: WO 03/072757 (2003-09-01), None
patent: WO 03/093290 (2003-11-01), None
patent: WO 04/000858 (2003-12-01), None
patent: WO 04/002422 (2004-01-01), None
patent: WO 04/002999 (2004-01-01), None
patent: WO 04/003138 (2004-01-01), None
patent: WO 04/007512 (2004-01-01), None
patent: WO 04/009020 (2004-01-01), None
patent: WO 04/028481 (2004-04-01), None
patent: WO 04/046159 (2004-06-01), None
Harry-O'kuru et al. Nucleotides & Nucleosides (1997), vol. 16, pp. 1457-1460.
Altmann et al, “The synthesis of 1′-methyl carbocyclic thymidine and its effect on nucleic acid duplex stability,”Synlett, Thieme Verlag, Stuttgart, De, 10:853-855 (1994).
Baginski, S. G, et al., “Mechanism of action of a pestivirus antiviral compound,”PNAS USA, 97(14):7981-7986 (2000).
Beigelman, L.N., et al, “Epimerization during the acetolysis of 3-O-acetyl-5-O-benzoyl-1,2-O-isopropylidene-3-C-methyl-α,D-ribofuranose. Synthesis of 3′-C-methylnucleosides with the β-D-ribo-and α-D-arabinoconfigurations,”Carbohydrate Research, 181:77-88 (1988).
Beigelman, L.N., et al, “A general method for synthesis of 3′-C-alkylnucleosides,”Nucleic Acids Symp. Ser., 9:115-118 (1981).
Berenguer, M., et al, “Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies,”Proceedings of the Association of American Physicians, 110(2), 98-112 (1998).
Carroll, S.S., et al., “Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs,”The Journal of Biological Chemistry, 278(14):11979-11984 (2003).
Czernecki, S., et al, “Synthesis of various 3′-branched 2′,3′-unsaturated pyrimidine nucleosides as potential anti-HIV agents,”J. Org. Chem., 57:7325-7328 (1992).
DeFrancesco, R., et al., “Approaching a new era for hepatitis C virus therapy: Inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase,”Antiviral Research, 58:1-16 (2003).
Faivre-Buet, V., et al, “Synthesis of 1′-deoxypsicofuranosyl-deoxynucleosides as potential anti-HIV agents,”Nucleosides&Nucleotides, 11(7):1411-1424 (1992).
Farkas, J., et al., “Nucleic acid components and their analogues. XCIV. Synthesis of 6-amino-9-(1-deoxy-β-D-psicofuranosyl)purine”,Collect. Czech. Chem. Commun.32:2663-2667 (1967).
Farkas, J., et al., “Nucleic acid components and their analogues. LXXIX. Synthesis of methyl 1-deoxy-D-psicofuranosides substituted at C(1)with halo atoms or a mercapto group,”Collect. Czech. Chem. Commun., 31:1535-1543 (1996).
Fedorov, I.I., et al, “3′-C-Branched 2′-deoxy-5-methyluridines: Synthesis, enzyme inhibition, and antiviral properties,”J. Med. Chem., 35(24):4567-4575 (1992).
Franchetti, P., et al., “2′-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies,”J. Med. Chem., 41(10):1708-1715 (1998).
Grouiller, A., et al., “Novel p-toluenesulfonylation and thionocarbonylation of unprotected thymine nucleosides,”Synlett, 1993, 221-222 (Mar. 1993).
Haraguchi, K., et al., “Preparation and reactions of 2′- and 3′- vinyl bromides of uracil nucleosides: Versatile synthons for anti-HIV agents,”Tetrahedron Letters, 32(28):3391-3394 (1991).
Haraguchi, K., et al., “Stereoselective synthesis of 1′-C-branched uracil nucleosides from uridine,”Nucleosides&Nucleotides, 14(3-5):417-420 (1995).
Harry-O'Kuru, R.E., et al., “A short, flexible route toward 2′-C-branched ribonucleosides”,J.Org. Chem., 62:1754-1759 (1997). (Scheme 11).
Harry-O'Kuru, R.E., et al., “2′-C-Alkylribonucleosides: Design, synthesis, and conformation,”Nucleosides&Nucleotides, 16(7-9): 1457-1460 (1997). [“Rogers” in #2; correct name in #7].
Hattori, H., et al, “Nucleosides and nucleotides. 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-b-D-ribo-pentofuranosyl)cytosine and -uracil,”J. Med. Chem., 41:2892-2902 (1998).
Hrebabecky, H., et al., “Nucleic acid components and their analogues. CXLIX. Synthesis of pyrimidine nucleosides derived from 1-deoxy-D-psicose,”Collect. Czech. Chem. Commun., 37:2059-2065 (1972).
Hrebabecky, H., et al. “Synthesis of 7- and 9β-D-psicofuranosylguanine an
LaColla Paulo
Sommadossi Jean-Pierre
Idenix Pharmaceuticals Inc.
King & Spalding LLP
Knowles, Esq. Sherry M.
Lewis Patrick
Universita Degli Studi Di Cagliari
LandOfFree
Methods and compositions for treating hepatitis C virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating hepatitis C virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating hepatitis C virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3743372